Yazdan Yazdanpanah to Male
This is a "connection" page, showing publications Yazdan Yazdanpanah has written about Male.
Connection Strength
0.199
-
Impact on disease mortality of clinical, biological, and virological characteristics at hospital admission and overtime in COVID-19 patients. J Med Virol. 2021 04; 93(4):2149-2159.
Score: 0.012
-
Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis. 2020 06; 20(6):697-706.
Score: 0.012
-
Assessing the cost-effectiveness of hepatitis C screening strategies in France. J Hepatol. 2018 Oct; 69(4):785-792.
Score: 0.010
-
Score for pulmonary tuberculosis in patients with clinical presumption of tuberculosis in a low-prevalence area. Int J Tuberc Lung Dis. 2017 12 01; 21(12):1272-1279.
Score: 0.010
-
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis. 2009 Nov 01; 49(9):1441-9.
Score: 0.006
-
Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2. Viruses. 2021 08 19; 13(8).
Score: 0.003
-
Sociodemographic characteristics and transmission risk factors in patients hospitalized for COVID-19 before and during the lockdown in France. BMC Infect Dis. 2021 Aug 13; 21(1):812.
Score: 0.003
-
Impact of the COVID-19 pandemic on the homeless: results from a retrospective closed cohort in France (March-May 2020). Clin Microbiol Infect. 2021 Oct; 27(10):1520.e1-1520.e5.
Score: 0.003
-
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-ß-1a and hydroxychloroquine in hospitalized patients with COVID-19. Clin Microbiol Infect. 2021 Dec; 27(12):1826-1837.
Score: 0.003
-
Long-Term Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectiousness Among Three Immunocompromised Patients: From Prolonged Viral Shedding to SARS-CoV-2 Superinfection. J Infect Dis. 2021 05 20; 223(9):1522-1527.
Score: 0.003
-
Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort. Proc Natl Acad Sci U S A. 2021 02 23; 118(8).
Score: 0.003
-
Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity. Nat Immunol. 2021 03; 22(3):322-335.
Score: 0.003
-
Association between renin-angiotensin-aldosterone system blockers and outcome in coronavirus disease 2019: analysing in-hospital exposure generates a biased seemingly protective effect of treatment. J Hypertens. 2021 02 01; 39(2):367-375.
Score: 0.003
-
Arterial Thrombotic Events in Adult Inpatients With COVID-19. Mayo Clin Proc. 2021 02; 96(2):295-303.
Score: 0.003
-
SARS-COV2 infection in 30 HIV-infected patients followed-up in a French University Hospital. Int J Infect Dis. 2020 Dec; 101:49-51.
Score: 0.003
-
A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. Sci Transl Med. 2020 09 02; 12(559).
Score: 0.003
-
Case report study of the first five COVID-19 patients treated with remdesivir in France. Int J Infect Dis. 2020 Sep; 98:290-293.
Score: 0.003
-
Treatment as prevention (TasP) and perceived sexual changes in behavior among HIV-positive persons: a French survey in infectious diseases departments in Paris. AIDS Care. 2020 07; 32(7):811-817.
Score: 0.003
-
Brief Report: Impact of ART Classes on the Increasing Risk of Cerebral Small-Vessel Disease in Middle-Aged, Well-Controlled, cART-Treated, HIV-Infected Individuals. J Acquir Immune Defic Syndr. 2019 08 15; 81(5):547-551.
Score: 0.003
-
Prescribers' experience and opinions on antimicrobial stewardship programmes in hospitals: a French nationwide survey. J Antimicrob Chemother. 2019 08 01; 74(8):2451-2458.
Score: 0.003
-
New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations. J Antimicrob Chemother. 2019 07 01; 74(7):2019-2023.
Score: 0.003
-
Concentration-response model of rilpivirine in a cohort of HIV-1-infected naive and pre-treated patients. J Antimicrob Chemother. 2019 07 01; 74(7):1992-2002.
Score: 0.003
-
HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen. J Antimicrob Chemother. 2019 06 01; 74(6):1679-1692.
Score: 0.003
-
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019 06; 6(6):e355-e363.
Score: 0.003
-
Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study. Pharmacotherapy. 2019 04; 39(4):514-520.
Score: 0.003
-
Illicit massive silicone injections always induce chronic and definitive silicone blood diffusion with dermatologic complications. Medicine (Baltimore). 2019 Jan; 98(4):e14143.
Score: 0.003
-
A case of thoracic actinomycosis presenting as sudden paraplegia. Rev Neurol (Paris). 2019 Jan - Feb; 175(1-2):89-92.
Score: 0.003
-
Costs associated with hospitalization in HIV-positive patients in France. AIDS. 2018 09 10; 32(14):2059-2066.
Score: 0.003
-
Pneumocystis Cytochrome b Mutants Associated With Atovaquone Prophylaxis Failure as the Cause of Pneumocystis Infection Outbreak Among Heart Transplant Recipients. Clin Infect Dis. 2018 08 31; 67(6):913-919.
Score: 0.003
-
Calendar trends in sexual behaviours in a cohort of HIV-infected MSM at the era of treatment as prevention of HIV infection. AIDS. 2018 08 24; 32(13):1871-1879.
Score: 0.003
-
Voluntary Community Human Immunodeficiency Virus Testing, Linkage, and Retention in Care Interventions in Kenya: Modeling the Clinical Impact and Cost-effectiveness. Clin Infect Dis. 2018 08 16; 67(5):719-726.
Score: 0.003
-
Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study. J Antimicrob Chemother. 2018 08 01; 73(8):2120-2128.
Score: 0.003
-
Contribution of brain imaging to the diagnosis of intracranial tuberculoma and other brain lesions in patients presenting with miliary tuberculosis. Med Mal Infect. 2018 Dec; 48(8):533-539.
Score: 0.003
-
High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort. J Antimicrob Chemother. 2018 06 01; 73(6):1665-1671.
Score: 0.003
-
Silent Cerebral Small-Vessel Disease Is Twice as Prevalent in Middle-Aged Individuals With Well-Controlled, Combination Antiretroviral Therapy-Treated Human Immunodeficiency Virus (HIV) Than in HIV-Uninfected Individuals. Clin Infect Dis. 2018 05 17; 66(11):1762-1769.
Score: 0.003
-
Serious neuropsychiatric adverse effects related to interaction between itraconazole and darunavir/ritonavir in an HIV-infected patient with cerebral histoplasmosis. J Antimicrob Chemother. 2018 04 01; 73(4):1108-1110.
Score: 0.003
-
Safety and efficacy of exposure to bedaquiline-delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia. Eur Respir J. 2018 03; 51(3).
Score: 0.003
-
Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine. Eur J Clin Pharmacol. 2018 Apr; 74(4):473-481.
Score: 0.003
-
No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir. J Antimicrob Chemother. 2018 Jan 01; 73(1):173-176.
Score: 0.003
-
Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study). HIV Med. 2018 03; 19(3):227-237.
Score: 0.003
-
The acceptability and effectiveness of a questionnaire for the identification of risk factors for HIV and hepatitis B and C: An observational study in general practice. Eur J Gen Pract. 2018 Dec; 24(1):60-67.
Score: 0.003
-
Strengthened Ebola surveillance in France during a major outbreak in West Africa: March 2014-January 2016. Epidemiol Infect. 2017 12; 145(16):3455-3467.
Score: 0.003
-
The negative impact of HBV/HCV coinfection on cirrhosis and its consequences. Aliment Pharmacol Ther. 2017 12; 46(11-12):1054-1060.
Score: 0.002
-
Outbreak of Pneumocystis jirovecii Infection Among Heart Transplant Recipients: Molecular Investigation and Management of an Interhuman Transmission. Clin Infect Dis. 2017 10 01; 65(7):1120-1126.
Score: 0.002
-
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. Lancet HIV. 2017 11; 4(11):e486-e494.
Score: 0.002
-
No relationship between late HIV diagnosis and social deprivation in newly diagnosed patients in France. HIV Med. 2018 03; 19(3):238-242.
Score: 0.002
-
Prevalence of respiratory viruses among adults, by season, age, respiratory tract region and type of medical unit in Paris, France, from 2011 to 2016. PLoS One. 2017; 12(7):e0180888.
Score: 0.002
-
Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort. J Antimicrob Chemother. 2017 06 01; 72(6):1745-1751.
Score: 0.002
-
Budget impact of antiretroviral therapy in a French clinic cohort. AIDS. 2017 06 01; 31(9):1271-1279.
Score: 0.002
-
Sub-Saharan African migrants have slower initial CD4+ cell recovery after combined antiretroviral treatment initiation than French natives. AIDS. 2017 06 01; 31(9):1323-1332.
Score: 0.002
-
Vaccination and blood sampling acceptability during Ramadan fasting month: A cross-sectional study in Conakry, Guinea. Vaccine. 2017 05 02; 35(19):2569-2574.
Score: 0.002
-
Disparities in HIV-1 transmitted drug resistance detected by ultradeep sequencing between men who have sex with men and heterosexual populations. HIV Med. 2017 10; 18(9):696-700.
Score: 0.002
-
Impact of respiratory viruses in hospital-acquired pneumonia in the intensive care unit: A single-center retrospective study. J Clin Virol. 2017 06; 91:52-57.
Score: 0.002
-
Contribution of alcohol use disorders on the burden of chronic hepatitis C in France, 2008-2013: A nationwide retrospective cohort study. J Hepatol. 2017 09; 67(3):454-461.
Score: 0.002
-
Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study. J Antimicrob Chemother. 2017 04 01; 72(4):1137-1146.
Score: 0.002
-
Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. Eur Respir J. 2017 03; 49(3).
Score: 0.002
-
Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial. HIV Clin Trials. 2017 05; 18(3):135-140.
Score: 0.002
-
The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study. BMC Infect Dis. 2017 02 21; 17(1):162.
Score: 0.002
-
Characteristics and consequences of medical care interruptions in HIV-infected patients in France. Epidemiol Infect. 2016 08; 144(11):2363-70.
Score: 0.002
-
Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr. 2010 Jul; 54(3):258-68.
Score: 0.002
-
Absence of infection in asymptomatic contacts of index SARS case in France. Euro Surveill. 2006; 11(1):40-1.
Score: 0.001
-
Introduction of SARS in France, March-April, 2003. Emerg Infect Dis. 2004 Feb; 10(2):195-200.
Score: 0.001